The head of the U.S. House of Representative’s oversight panel called on three drugmakers to turn over documents as part of an ongoing congressional review over generic drug price increases and accused the companies of “apparent efforts to stonewall” the probe.
Days after the U.S. FDA revealed data manipulation was involved in the early studies of Novartis’ multi-million dollar gene therapy for SMA, U.S. Senate members demanded the regulatory agency take action against AveXis, the company that developed Zolgensma.
A look at potential new developments important to health communications and marketing.
Canada’s main pharmaceutical lobby group urged the government not to wait for drug shortages before responding to U.S. plans to import Canadian drugs, according to documents seen by Reuters.
The Trump administration took a step toward allowing the importation of medicines from Canada, an action the president has advocated as a way to bring cheaper Rx drugs to Americans.
Main pharmaceutical industry lobbying group PhRMA and some drugmakers met with President Donald Trump to voice opposition to a bipartisan U.S. Senate bill that aims to lower prescription drug prices.
Senate Finance Committee Chairman and Republican Chuck Grassley and the panel’s leading Democrat, Senator Ron Wyden, announced a bipartisan proposal to lower the Rx drug prices.
Canada opposes any U.S. plans to buy Canadian prescription drugs that might threaten the country’s drug supply or raise costs for its own citizens – officials told U.S. authorities – in a new setback to the Trump administration’s efforts to tackle high drug prices, according to documents obtained by Reuters.
Three U.S. senators introduced a resolution in support of a moratorium and other limits on gene editing embryos.
Lawmakers on the U.S. Senate Judiciary Committee urged the Trump administration to conduct a scientific review of a Justice Department-backed bill to classify all illicit chemical knockoffs of the potent painkiller fentanyl in the same legal category as heroin.